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The endocannabinoid system (ECS) plays a critical
role in obesity development. The pharmacological
blockade of cannabinoid receptor type 1 (CB1) has
been shown to reduce body weight and to alleviate
obesity-related metabolic disorders. An unsolved
question is at which anatomical level CB1 modulates
energy balance and the mechanisms involved in its
action. Here, we demonstrate that CB1 receptors ex-
pressed in forebrain and sympathetic neurons play
a key role in the pathophysiological development of
diet-induced obesity. Conditional mutant mice lack-
ing CB1 expression in neurons known to control
energy balance, but not in nonneuronal peripheral
organs, displayed a lean phenotype and resistance
to diet-induced obesity. This phenotype results
from an increase in lipid oxidation and thermogene-
sis as a consequence of an enhanced sympathetic
tone and a decrease in energy absorption. In conclu-
sion, CB1 signaling in the forebrain and sympatheticCneurons is a key determinant of the ECS control of
energy balance.INTRODUCTION
The endocannabinoid system (ECS) has emerged as a key player
in both central and peripheral functions related to energy metab-
olism (Pagotto et al., 2006; Kunos et al., 2008). Initial studies
based on the evidence that the cannabinoid receptor type 1
(CB1) was exclusively present in the brain all attributed the ability
of the ECS to modulate food intake to a central site of action
(Pagotto et al., 2006). However, new evidence has accumulated,
which suggests that the ECS might regulate energy balance not
exclusively at central sites. In fact, CB1 receptors and their
ligands were also found in several peripheral organs (Pagotto
et al., 2006; Kunos et al., 2008). Consequently, it has emerged
that CB1 might control body weight by food intake-independent
mechanisms. Complete deletion of CB1 in mice (CB1-KO) led
to decreased fat mass, reduced body weight, and resistance
to develop obesity (Cota et al., 2003; Ravinet Trillou et al.,
2004). In addition, beneficial food intake-independent effects
on metabolism were demonstrated by using CB1 antagonistsell Metabolism 11, 273–285, April 7, 2010 ª2010 Elsevier Inc. 273
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CB1 Receptors and Energy Metabolism(Ravinet Trillou et al., 2004). Recent studies suggested that the
sustained body weight loss induced by CB1 antagonists after
the initial decrease in food intake might be explained by an effect
of the drugs on energy expenditure. Blockade of CB1 in obese
animals induces an array of pharmacological effects, including
stimulation of lipolysis and fatty acid oxidation (Herling et al.,
2008). However, the anatomical location of the CB1 receptors
involved in these functions is still under discussion (Kunos
et al., 2009). This is an important point because rimonabant,
the first CB1 antagonist used for the treatment of obesity, has
been recently withdrawn from the market due to psychiatric
side effects (Akbas et al., 2009). The generation of CB1 antago-
nists selectively acting at peripheral organs could be a promising
way to preserve the metabolic effects of CB1 blockade without
causing side effects due to CB1 inhibition in neural circuits regu-
lating mood and anxiety (McElroy et al., 2008; LoVerme et al.,
2009). Nevertheless, the identification of the anatomical site(s)
where the ECS exerts its effects on energy balance and metab-
olism is mandatory before further screening for potentially more
selective and safer drugs. Thus, in order to single out the major
anatomical sites underlying the ECS-dependent regulation of
energy balance and metabolism, we studied conditional mutant
mice (CaMK-CB1-KO mice) characterized by a CB1 deletion in
forebrain neurons (Marsicano et al., 2003) and compared their
phenotype to that of conventional CB1-KO (Marsicano et al.,
2002) and of mice treated with the CB1 antagonist rimonabant.
RESULTS
Anatomical Characterization of CB1 Expression
in CaMK-CB1-KO Mice
CaMK-CB1-KO conditional mutant mice were obtained using the
Cre/loxP system by crossing CB1
flox/flox mutants with CaMKIIa-
iCre transgenic mice (Casanova et al., 2001; Marsicano et al.,
2003). CaMKIIa-iCre mice express the recombinase in the great
majority of adult forebrain neurons, with the exclusion of cortical
GABAergic interneurons (Casanova et al., 2001). Importantly,
brain regions known to control energy balance (e.g., the hypo-
thalamus) do express the Cre recombinase in these mutant
mice (Casanova et al., 2001).
As expected, the abundant expression of CB1 mRNA in
intrinsic neurons of the hypothalamus (Cota et al., 2003) (Figures
1A and 1B) was absent in CaMK-CB1-KO mice (Figures 1A
and 1B). In the hypothalamus, CB1 protein was found mainly
on axon terminals of both extrinsic and intrinsic neurons (Witt-
mann et al., 2007). Immunohistochemistry (IHC) revealed that
the intensely CB1-positive meshwork in the hypothalamus of
CaMK-CB1-WT was virtually absent in CaMK-CB1-KO mice
(Figures 1A and 1B).
The nucleus of the solitary tract (NTS) is one of the main
funneling sites of energy balance regulation (Grill and Hayes,
2009). It receives inputs from both higher brain regions (as hypo-
thalamus and cerebral cortex) and vagal ganglions (i.e., nodose
ganglion) and regulates output efferents that control the func-
tions of several peripheral organs modulating energy metabo-
lism (Grill and Hayes, 2009). Similar to the hypothalamus, CB1
receptors are present in both afferent and efferent neurons of
the NTS (Tsou et al., 1998). Intrinsic NTS neurons of CaMK-
CB1-KO mice still expressed CB1 mRNA, as revealed by double274 Cell Metabolism 11, 273–285, April 7, 2010 ª2010 Elsevier Inc.in situ hybridization (DISH) using glucagon-like peptide 1,
a marker of NTS neurons (Figure 1C). However, no CB1 protein
was found in this region (Figure 1C). Thus, these data indicate
that the afferent terminals in the NTS of CaMK-CB1-KO mice
do not contain CB1 protein. Because CB1 protein is expressed
generally at presynaptic level, the preserved CB1 mRNA expres-
sion in intrinsic NTS neurons suggests that CB1 protein at the
axonal terminals of these neurons is present in mutant mice.
CB1 mRNA expression is preserved in both rostral and distal
nodose ganglion (Figures 1D and 1F and Figure S1A available
online) of CaMK-CB1-KO, and CB1 immunoreactivity is
also unchanged in these mutant mice as compared to WT
(Figure S1B). Thus, CB1 signaling on vagal afferents to NTS
and to the nodose ganglion is maintained in CaMK-CB1-KO
mice. CB1 mRNA is also present in a subset of dopamine-b-
hydroxylase (DBH)-expressing neurons of superior cervical
sympathetic ganglia but is significantly reduced as compared
to WT (Figure 1E). The neuroanatomical analysis was in agree-
ment with QT-PCR data showing a nearly 60% reduction in the
ratio between CB1 and DBH mRNA expression in superior
cervical ganglia of CaMK-CB1-KO mice (data not shown).
Conversely, CB1 expression was preserved in nonneuronal
peripheral organs (Figures 1F and 1G).
CaMK-CB1-KO Mice Are Lean and Unresponsive to the
Acute Action of the CB1 Antagonist Rimonabant
The monitoring of body weight in mice maintained on standard
diet (SD) revealed that CaMK-CB1-KO mice had a significantly
lower body weight than their WT (Figure 2A). However, when
compared to complete CB1-KO mice, the phenotype of condi-
tional mutants was less pronounced (Figures 2B and 2C), sug-
gesting that CB1 expressed in forebrain and sympathetic
neurons does not fully account for the lean phenotype observed
in the complete CB1-KO mice on SD.
The CB1 antagonist rimonabant exerts profound CB1-depen-
dent effects on food intake, body weight, and lipid oxidation
(Herling et al., 2008). To investigate whether these effects are
dependent upon CB1 in forebrain and sympathetic neurons,
CaMK-CB1-KO and WT littermates were treated with rimona-
bant. The administration of the CB1 antagonist acutely reduced
body weight and respiratory quotient (RQ) of CaMK-CB1-WT
mice, but not of CaMK-CB1-KO mice (Figures 2D and 2E).
Furthermore, because the effects of acute CB1 blockade are
particularly evident in stimulated conditions (Di Marzo et al.,
2001), we evaluated rimonabant action on fasting-induced over-
eating in conditional mutant mice. After 24 hr of fasting, CaMK-
CB1-WT mice ate significantly more than CaMK-CB1-KO mice
(Figure 2F). Under these experimental conditions, rimonabant
(3 mg/kg i.p.) significantly decreased food intake in CaMK-
CB1-WT, unlike in CaMK-CB1-KO (Figure 2F). These data indi-
cate that CB1 expressed in forebrain and sympathetic neurons
is an important mediator of the acute effects of rimonabant on
food intake, body weight, and lipid oxidation.
CB1 in Forebrain and Sympathetic Neurons
Regulates Diet-Induced Obesity
To assess the role of CB1 in diet-induced obesity (DIO), CaMK-
CB1-KO, complete CB1-KO, and their WT littermates were main-
tained on a mild high-fat diet (HFD, 40% fat content) for 12 weeks.
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Figure 1. CB1 mRNA and Protein Distribution in CaMK-CB1-KO Mice
(A) CB1 mRNA expression detected by ISH (top) and staining of CB1 protein by IHC (bottom) in the whole hypothalamus. Scale bar, 200 mm.
(B) ISH (top) and IHC (bottom) for CB1 in the paraventricular nucleus of the hypothalamus (PVN, encircled scattered lines in top panels). Scale bar, 50 mm. (III) third
ventricle.
(C) (Top) DISH for CB1 mRNA (black dots) and glucagon-like peptide 1 (GLP-1) mRNA (red color) in the nucleus of the solitary tract (NTS). Scale bar, 30 mm.
(Bottom) CB1 protein in the NTS. (Triangle) Dorsal motor nucleus of the vagus. (Square) Hypoglossal nucleus. (IV) Fourth ventricle. Scale bar, 200 mm.
(D) ISH for CB1 mRNA (in red) in the nodose ganglia. Scale bar, 50 mm.
(E) DISH for CB1 mRNA (black dots) and dopamine-b-hydroxylase (DBH) (red color) and QT-PCR analysis of the ratio CB1/DBH mRNA expression in the superior
cervical sympathetic ganglia. Scale bar, 1.5 mm; n = 4 ganglia per group; data are mean ± SEM. ***p% 0.0005.
(F) CB1 mRNA expression by QT-PCR in the hypothalamus and in peripheral tissues of CaMK-CB1-WT and KO mice (n = 6 per genotype). CB1-KO mice organs
are negative control. WAT, white adipose tissue; BAT, brown adipose tissue, RNG, rostral nodose ganglion; DNG, distal nodose ganglion; n.d., not detected. Data
are mean ± SEM.
(G) Schematic representation of areas of CB1 deletion in CaMK-CB1-KO mice, referring to regions implicated in energy control. Presynaptic CB1 protein is in red.
Black crosses indicate CB1 deletion. Dashed lines indicate reduced CB1 expression. Hyp, hypothalamus; NTS, nucleus of the solitary tract.
See also Figure S1.
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CB1 Receptors and Energy MetabolismTo study CB1 expression in peripheral tissues after HFD, we
analyzed, by QT-PCR, CB1 mRNA levels in white adipose tissue
(WAT), brown adipose tissue (BAT), and liver of CaMK-CB1-KO
and -WT. QT-PCR analysis in BAT and liver of CaMK-CB1-WT
mice revealed that CB1 mRNA expression was increased in
HFD, as compared to SD (Figure 3A). This increase remained sig-
nificant only in the liver, but not in the BAT, of CaMK-CB1-KO. No
differences were detected in WAT of both CaMK-CB1-KO and
-WT mice on HFD compared to SD (Figure 3A).
Both CaMK-CB1-KO and complete CB1-KO mice had a signif-
icantly lower body weight than their WT under HFD (Figures 3BCand 3C). However, when body weight was expressed as
percentage of the initial weight, CaMK-CB1-KO mice gained
significantly less weight than WT or CB1-KO mice (Figure 3D).
Of interest, the weight gain of complete CB1-KO was not
different from WT. Furthermore, a chronic treatment with rimona-
bant (10 mg/kg; 32 days, daily) did not affect the body weight of
CaMK-CB1-KO mice under HFD, whereas it reduced body
weight gain in CaMK-CB1-WT (Figure 3E). A diet higher in fat
content (60%, super HFD) caused a greater body weight gain
in WT mice, but not in CaMK-CB1-KO mice (Figures 3F and
3G). Thus, these data exclude that the resistant phenotypeell Metabolism 11, 273–285, April 7, 2010 ª2010 Elsevier Inc. 275
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Figure 2. Characterization of CaMK-CB1-KO Mice
during Standard Diet
(A) Average body weight of CaMK-CB1-WT (black circles)
and CaMK-CB1-KO mice (red circles) kept on SD for
a period of 12 weeks (n = 18 per genotype). *p < 0.05.
(B) Average body weight of CB1-WT mice (black circles)
and complete CB1-KO mice (gray circles) kept on SD for
a period of 12 weeks (n = 18 per genotype). **p < 0.005.
(C) Body weight of CaMK-CB1-KO and complete CB1-KO
mice, expressed as percentage of WT mice ± SEM. Values
for CaMK-CB1-WT and CB1-WT were cumulated since not
statistically different (black bar). Red dashed bar, CaMK-
CB1-KO; gray bar, CB1-KO mice. *p < 0.05.
(D) Weight loss of CaMK-CB1-WT mice (black bar) (n = 6)
and CaMK-CB1-KO (red dashed bar) (n = 5) 24 hr after
rimonabant administration (10 mg/kg i.p.). **p < 0.005.
(E) Average 24 hr respiratory quotient (RQ) measured every
hour for two days in CaMK-CB1-WT mice (n = 7) and
CaMK-CB1-KO (n = 6). On the first day, animals were
treated with vehicle; rimonabant treatment (10 mg/kg
i.p.) started at the beginning of day 2. ***p < 0.0005. White
bars, vehicle mice; black bars, rimonabant mice.
(F) Cumulative food intake within 1 hr after fasting of
CaMK-CB1-WT mice (black bars) and CaMK-CB1-KO
mice (white bars) treated with vehicle or rimonabant
(3 mg/kg i.p.), respectively. n = 10 per genotype. ***p <
0.0005.
Data represent mean ± SEM.
Cell Metabolism
CB1 Receptors and Energy Metabolismobserved in CaMK-CB1-KO mice was displayed only under
conditions of moderate DIO. Furthermore, we measured the total
adiposity, hepatic steatosis (by hepatic triglyceride measure-
ment), and plasma metabolic profile of CaMK-CB1-KO,
CB1-KO, and their respective WT mice after 12 weeks of HFD.
No significant difference was observed between WT littermates
of CaMK-CB1-KO mice and CB1-KO mice, neither under SD nor
under HFD (data not shown). Thus, WT values were cumulated to
improve readability of the results. As shown in Figures 4A and
4B, chronic HFD did not significantly increase adipose tissue
content in CaMK-CB1-KO and CB1-KO mice, as opposed to
WT. Hepatic triglycerides content was significantly increased in
WT animals after HFD administration, but not in CB1-KO and
CaMK-CB1-KO mice (Figure 4C). The plasma levels of leptin,
insulin, glucose, free fatty acids (FFA), and triglycerides were
significantly increased in WT animals, but not in CB1-KO and
CaMK-CB1-KO mice, after the same HFD (Figure 4D). Total
cholesterol increased in WT animals after HFD, but no significant
changes were observed in either CB1-KO or CaMK-CB1-KO
mice (Figure 4D). Altogether, these results suggest that CB1276 Cell Metabolism 11, 273–285, April 7, 2010 ª2010 Elsevier Inc.signaling in forebrain and sympathetic neurons
plays an important role in body weight gain, fat
accumulation, and metabolic alterations associ-
ated with chronic HFD consumption.
Metabolized Energy and Lipids Utilization
under HFD Are Modulated by CB1 in
Forebrain and Sympathetic Neurons
CaMK-CB1-KO and CB1-KO mice under HFD
showed a total food intake comparable to their
WT controls (Figures 5A and 5B). Nevertheless,CaMK-CB1-KO mice had a significantly lower feed efficiency
than either WT or complete CB1-KO mice (Figure 5C). Thus,
CB1 in forebrain and sympathetic neurons regulates the conver-
sion of energy intake into fat accumulation and body weight gain.
To analyze the mechanisms underlying the reduced feed
efficiency of CaMK-CB1-KO mice, we evaluated energy homeo-
stasis. First, as compared to their WT littermates, CaMK-CB1-
KO mice exhibited a less-efficient absorption of energy, as
indicated by the increase in the energy content of the feces
(Figure 5D). CaMK-CB1-KO mice and their WT littermates had
comparable metabolic rate (Figure 5E) and body temperature
(data not shown). Conversely, the RQ was significantly reduced
in the mutant animals during the night, the active period of mice
(Figure 5F). No difference in night and day food intake was found
between CaMK-CB1-KO and CaMK-CB1-WT mice (data not
shown), thus allowing us to exclude that a different amount of
food ingested in the dark period influenced the RQ. As in SD
(Figure 2E), the acute administration of rimonabant in HFD
reduced RQ in CaMK-CB1-WT mice, but not in CaMK-CB1-KO
mice (Figure 5G).
Cell Metabolism
CB1 Receptors and Energy MetabolismCB1 in Forebrain and Sympathetic Neurons Regulates
BAT Functions and Thermogenesis
Low feed efficiency may be also explained by increased BAT
thermogenic and mitochondrial activities. Of note, peroxisome
proliferator-activated receptor g coactivator 1a (PGC-1a),
nuclear respiratory factor-1 (NRF-1), mitochondrial transcription
factor A (Tfam) (master regulators of mitochondrial biogenesis),
and cytochrome c (Cyt c) and cytochrome c oxidase IV (COX
IV) (two mitochondrial proteins involved in oxidative phosphory-
lation) mRNA levels, as well as mitochondrial DNA amount
and citrate synthase activity (biomarkers of mitochondrial mass
and function), were significantly increased in BAT of CaMK-
CB1-KO as compared to WT (Figure 6A). Western blot analysis
confirmed the QT-PCR data. In fact, an increase in PGC-1a,
COX IV, and Cyt c protein levels in the BAT of CaMK-CB1-KO
mice, as compared to WT mice, was observed (Figure S2A).
Furthermore, mRNA levels of uncoupling protein 1 (UCP-1)
were significantly increased in BAT of CaMK-CB1-KO mice, as
compared to WT mice (Figure 6A), suggesting an increased ther-
mogenic capacity in the conditional mutant mice. To test this
hypothesis, we exposed HFD-fed CaMK-CB1-KO mice to
a thermal challenge. Body temperature and O2 consumption
were significantly higher in CaMK-CB1-KO mice than in CaMK-
CB1-WT mice after cold exposure (+6
C) (Figures 6B and 6C),
thus suggesting that the lack of CB1 in the forebrain neurons
improves the thermogenic responses and increases energy
expenditure. In vivo positron emission tomography (PET) anal-
ysis revealed that the uptake of 2-deoxy-2-[18F]fluoro-D-glucose
(18F-FDG) was markedly increased in cold-exposed HFD-fed
CaMK-CB1-KO mice, as compared to CaMK-CB1-WT mice
(Figures 6D and 6E). Moreover, rimonabant treatment increased
the 18F-FDG uptake in CaMK-CB1-WT mice, but not in CaMK-
CB1-KO mice (Figure 6E). These data strongly suggest that the
activation of neuronal CB1 signaling modulates BAT thermogen-
esis during HFD and that CB1 in forebrain and sympathetic
neurons has a major role in the regulation of this function.
CB1 in Forebrain and Sympathetic Neurons Regulates
Energy Balance by Modulating the Sympathetic Tone
To determine the mechanism leading to the energy balance
changes observed in CaMK-CB1-KO mice under HFD, we inves-
tigated the activity of the sympathetic nervous system (SNS).
HFD-fed CaMK-CB1-KO mice had a marked increase in plasma
norepinephrine (NE) levels, as compared to WT (no changes in
plasma epinephrine and dopamine; data not shown), and similar
data were obtained in complete CB1-KO mice (Figure 6F). To
further substantiate whether the changes in BAT metabolism
were due to increased SNS activity, we investigated the uptake
of the PET tracer 11C-meta-hydroxyephedrine (a NE analog)
(Thackeray et al., 2007) into the BAT of WT, CaMK-CB1-KO,
and CB1-KO mice. Similar increases in tracer uptake were
observed in both CaMK-CB1-KO and CB1-KO mice as
compared to WT at 24C, suggesting an increased NE turnover
in this tissue (Figure 6G). Consistently, WT mice chronically
treated with rimonabant exhibited an increase in BAT NE turn-
over, as compared to vehicle-treated WT mice (Figure 6H).
Moreover, a greater difference in tracer uptake was observed
in both conditional and complete KO mice, as compared to
WT, under hypothermia (+6C) (Figure 6G). Altogether, theseCdata suggest that the increased thermogenesis of CaMK-CB1-
KO mice is caused by an increased SNS activity in the BAT,
implying that CB1 receptors located in principal forebrain and
sympathetic neurons play a key regulator role on peripheral
SNS activity. This finding was further substantiated by the
in vivo analysis of FDG uptake and ex vivo analysis of mitochon-
drial activity in the BAT of cold-exposed (+6C) animals after
sympathetic denervation. In vivo small animal PET data demon-
strated that the higher thermogenic function of the BAT of
CaMK-CB1-KO mice is completely abolished after both chemi-
cal (6-OH-dopamine, 6-OH-DA) and surgical sympathectomy
(Figure 6E). Moreover, the increase in BAT thermogenesis
caused by rimonabant administration is also completely lost
after sympathectomy (Figure 6E). Ex vivo analysis of mitochon-
drial activity in cold-exposed animals after chemical sym-
pathectomy was in agreement with PET data showing that the
improved mitochondrial and thermogenic functions of the BAT
of CaMK-CB1-KO were lost after sympathectomy (Figure S2B).
Altogether, these results demonstrate that an increased
NE-mediated sympathetic tone is responsible for the higher
thermogenesis in CaMK-CB1-KO mice.
DISCUSSION
This study demonstrates that CB1 receptors expressed in fore-
brain and sympathetic neurons play a pivotal role in the regula-
tion of energy balance, which is particularly evident in DIO.
Several results support this conclusion: (1) Systemic administra-
tion of rimonabant, which antagonizes both neuronal and non-
neuronal CB1, does not affect body weight, food intake, and
energy control in CaMK-CB1-KO mice, both under SD or HFD;
(2) Whereas CaMK-CB1-KO mice show a milder lean phenotype
than CB1-KO mice under SD, their metabolic profile and fat
content become indistinguishable after prolonged exposure to
HFD; and (3) CaMK-CB1-KO mice are resistant to DIO because
of increased thermogenesis and overactivity of the SNS.
The anatomical characterization of CB1 expression in CaMK-
CB1-KO mice demonstrates that this animal model lacks CB1
protein in glutamatergic forebrain-projecting neurons in the
hypothalamus and in the NTS while still preserving the receptor
on distal terminals of NTS neurons and on peripheral organs.
However, CaMK-CB1-KO mice have a partial deletion of CB1 in
the sympathetic ganglia. Thus, the observed phenotype is the
result of the reduced ECS signaling at the level of CB1 expressed
in the forebrain and/or sympathetic neurons.
Our data also show that CB1 receptors in these locations exert
an important role in the control of the metabolic plasmatic profile
and hepatic steatosis in DIO. However, this could be secondarily
related to the resistance to body weight gain of CaMK-CB1-KO
mice and not due to a direct control by CB1 receptors expressed
at these sites. For this reason, our data do not rule out that
peripheral CB1 blockade could directly improve peripheral
metabolism, as recently demonstrated (Nogueiras et al., 2008;
Osei-Hyiaman et al., 2008; Cota et al., 2009).
Of interest, the overall food intake of conditional mutant mice
in HFD is similar to that of WT controls, suggesting that CB1
receptors control energy balance by other mechanisms than
food intake. Indeed, our data show that reduced CB1 signaling
at forebrain and sympathetic neurons counteracts the weightell Metabolism 11, 273–285, April 7, 2010 ª2010 Elsevier Inc. 277
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CB1 Receptors and Energy Metabolismgain associated to HFD due to a reduction of metabolized energy
and stimulation of lipid oxidation. Thus, blockade of CB1
signaling at these sites is necessary to induce lipid oxidation,
a phenomenon observed during chronic treatment with CB1
antagonists (Herling et al., 2008).
Furthermore, CaMK-CB1-KO mice display upregulated mito-
chondrial biogenesis and enhanced thermogenic activity in the
BAT. These data are in agreement with previous studies demon-
strating that CB1 blockade promotes energy dissipation through
mitochondrial heat production in the BAT, activation of futile
cycles, and restoration of mitochondrial biogenesis in WAT of
HFD-fed mice (Jbilo et al., 2005; Tedesco et al., 2008). Of note,
the increased fatty acid oxidation and the elevation of several
indexes of cellular energy dissipation seem to account for the
lower feed efficiency observed in CaMK-CB1-KO mice. Thus,
the present findings suggest that CB1 receptors on forebrain
and sympathetic neurons play a necessary role in the ECS
modulation of energy balance.
Our data demonstrate that CB1 receptors regulate energy
balance by modulating the SNS. Indeed, we found an elevated
sympathetic noradrenergic tone in CaMK-CB1-KO mice and an
increased NE turnover in the BAT of CaMK-CB1-KO mice, sug-
gesting that enhanced SNS activity is the factor responsible for
the increased functional activity of the BAT in CaMK-CB1-KO
mice. This conclusion is substantiated by two observations:
(1) During acute exposure to cold, a condition stimulating
thermogenesis via SNS activation, CaMK-CB1-KO displayed
a higher NE turnover of BAT and increased BAT functional
activity, and they preserved their metabolic rate and body
temperature; and (2) The increased BAT functional activity is
lost in CaMK-CB1-KO mice after both chemical and surgical
sympathectomy.
The second important finding of this study is the demonstra-
tion that rimonabant modulates SNS activity and energy
metabolism mainly through CB1 expressed in forebrain and
sympathetic neurons. Indeed, rimonabant-induced BAT thermo-
genesis under cold exposure was comparable to that observed
in untreated CaMK-CB1-KO mice. Moreover, sympathectomy
reduced BAT activity of both CaMK-CB1-KO and WT mice
treated with rimonabant. This last observation is in agreement
with recent data showing that the effects of rimonabant on
energy expenditure and thermogenesis are attenuated by BAT
denervation (Verty et al., 2009).Figure 3. Phenotype of CaMK-CB1-KO Mice during High-Fat/Super Hi
(A) CB1 mRNA expression by QT-PCR in the white adipose tissue (WAT), brown a
with SD (white columns) or HFD (black columns). n = 7 per genotype and diet. A
(B) Body weight of CaMK-CB1-WT (black triangles) and CaMK-CB1-KO mice (re
(C) Body weight of CB1-WT mice (n = 25) (black triangles) and complete CB1-KO
(D) Weight gain expressed as percentage of initial weight in CaMK-CB1-KO (re
**p < 0.005 CaMK-CB1-KO versus WT mice; #p < 0.05 CaMK-CB1-KO versus C
not statistically different.
(E) Weight change expressed as percentage of initial weight in mice daily treated
vehicle (n = 6). (Red triangles) CaMK-CB1-KO vehicle (n = 5). (Blue squares) CaMK
#p < 0.0005 CaMK-CB1-WT rimonabant versus CaMK-CB1-WT vehicle; ***p < 0
(F) Body weight of CaMK-CB1-WT (black triangles) and CaMK-CB1-KO mice (red
(G) Weight gain in CaMK-CB1-WT and CaMK-CB1-KO mice fed with mild HFD
***p < 0.0005.
Data represent mean ± SEM.
CExposure to HFD stimulates ECS activity by enhancing endo-
cannabinoids production (Kunos et al., 2008). Due to the inhibi-
tory effects of CB1 signaling, the HFD-induced activation of the
ECS likely dampens neuronal pathways controlling SNS activity,
leading to decreased SNS activity that, in turn, favors energy
storage and fat accumulation. Conversely, in CaMK-CB1-KO
mice, the reduced ECS signaling at the level of forebrain and/
or sympathetic neurons favors SNS overactivity, thus leading
to the lean phenotype observed, particularly under HFD. Consid-
ering that HFD increases general ECS activity, a possible inter-
pretation of our data is that, in conditions of excessive energy
intake, CB1 signaling in forebrain and/or sympathetic neurons
is particularly involved in limiting SNS overactivation during
DIO. Importantly, the activation of presynaptic CB1 receptors is
known to inhibit norepinephrine release and consequently
reduce sympathetic ‘‘tone’’ onto peripheral tissues (Kunos
et al., 2008); therefore, it is possible that CB1 reduction in sympa-
thetic ganglia is the factor leading to the increased sympathetic
activation in the mutant mice. However, an alternative possibility
is that central CB1 signaling might indirectly regulate sympa-
thetic activity through descending pathways. Further studies
using mutant mice with exclusive and complete deletion of
CB1 in sympathetic ganglia will reveal the relative contribution
of central nervous system versus SNS endocannabinoid
signaling in the control of peripheral energy metabolism.
Finally, we have also demonstrated that deletion of CB1 in
forebrain and sympathetic neurons influences CB1 expression
in peripheral organs. CaMK-CB1-KO mice, as opposed to WT
mice, did not increase CB1 expression in the BAT after HFD.
This supports the existence of a ‘‘vicious ECS cycle,’’ in which
CB1 signaling might promote itself in pathological conditions,
thus contributing to the worsening of the disease.
The present findings might have an important impact on clin-
ical practice. CB1 receptor antagonists have been recently
proposed as antiobesity agents and have been successfully
tested in humans in relation to their ability to reduce body weight
and improve several metabolic parameters (Scheen, 2008; Addy
et al., 2008). However, their clinical use has been recently halted
by the European Medicines Agency for the increased incidence
of psychiatric side effects (Akbas et al., 2009) due to their action
on CB1 located in brain areas regulating mood and response to
stress. Therefore, the selective targeting of peripheral CB1
antagonists unable to cross the blood brain barrier is the nextgh-Fat Diet
dipose tissue (BAT), and liver of CaMK-CB1-WT and CaMK-CB1-KO mice fed
U, arbitrary units.
d triangles) during the 12 weeks of HFD. n = 24 per genotype. ***p < 0.0005.
mice (n = 20) (gray diamonds) during the 12 weeks of HFD. ***p < 0.0005.
d triangles), complete CB1-KO (gray diamonds), and their WT (black circles).
B1-KO. The values of the CaMK-CB1-WT and CB1-WT were cumulated, since
with rimonabant (10 mg/kg i.p.) for 32 days. (Black triangles) CaMK-CB1-WT
-CB1-WT rimonabant (n = 7). (Green circles) CaMK-CB1-KO rimonabant (n = 6).
.0005 CaMK-CB1-WT rimonabant versus CaMK-CB1-KO rimonabant.
triangles) during 12 weeks of super HFD (n = 5 per genotype).
(40% of fat) (white bars) or super HFD (60% of fat) (black bars). *p < 0.05;
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Figure 4. Characterization of CaMK-CB1-KO Mice during High-Fat Diet
(A) Three-dimensional visualization of skeleton, visceral adipose tissue (red), and subcutaneous adipose tissue (blue) from in vivo micro-CT images of a WT on SD,
WT on HFD, CaMK-CB1-KO on HFD, and complete CB1-KO on HFD, respectively. (Top) Frontal views. (Bottom) Lateral views.
(B) Quantification of total fat content (as percentage of body weight) by in vivo micro-CT analysis in WT mice fed on SD (white bar, n = 15), WT mice fed on HFD
(black bar, n = 16), CaMK-CB1-KO mice fed on HFD (red dashed bar, n = 11), and complete CB1-KO mice on HFD (gray bar, n = 13). ***p < 0.0005.
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Figure 5. Energy Homeostasis in CaMK-CB1-KO
Mice on High-Fat Diet
(A) Food intake of CaMK-CB1-WT (black triangles) and
CaMK-CB1-KO mice (red triangles) during the 12 weeks
of HFD (n = 24 per genotype).
(B) Food intake of CB1-WT (n = 25) (black triangles) and
CB1-KO mice (n = 20) (gray diamonds) during the 12 weeks
of HFD.
(C) Feed efficiency of WT (black bar), CaMK-CB1-KO (red
dashed bar), and complete CB1-KO mice (gray bar) during
the 12 weeks of HFD (n = 20 per genotype). *p < 0.05;
**p < 0.005. Data are expressed as percentage of WT.
The values of the CaMK-CB1-WT and CB1-WT mice
were grouped since not statistically different.
(D) Daily energy loss (24 hr energy content by bomb
calorimetry). CaMK-CB1-WT (n = 6, black bar) and
CaMK-CB1-KO (n = 7, dashed red bar) fed with HFD.
*p < 0.05.
(E) Metabolic rate at night (7:00 PM–7:00 AM) and during
the day (7:00 AM–7:00 PM) in CaMK-CB1-WT (n = 5, black
bar) and CaMK-CB1-KO mice (n = 6, dashed red bar) on
HFD.
(F) Average RQ at night (7:00 PM–7:00 AM) and during the
day (7:00 AM–7:00 PM) in CaMK-CB1-WT (n = 5, black bar)
and CaMK-CB1-KO mice (n = 6, dashed red bar) on HFD.
*p < 0.05.
(G) Average RQ measured every hour for two days in
CaMK-CB1-WT (n = 7) and CaMK-CB1-KO (n = 6) fed
with HFD. On the first day, animals were treated
with vehicle; rimonabant treatment (10 mg/kg i.p.) started
at the beginning of day 2. ***p < 0.0005. White bars,
vehicle-treated mice; black bars, rimonabant-treated
mice.
Data represent mean ± SEM.
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CB1 Receptors and Energy Metabolismpredictable step in order to minimize side effects and, at the
same time, retain the favorable metabolic actions due to CB1
inhibition at the level of the adipose tissue, liver, skeletal muscle,
and endocrine pancreas (Kunos et al., 2009). Our results point to
a key role of CB1 expressed in forebrain neurons and sympa-
thetic terminals in the control of energy metabolism but leave
open the possibility that nonblood brain barrier-penetrating
drugs (McElroy et al., 2008; LoVerme et al., 2009), acting at
presynaptic CB1 receptors on peripheral neurons and thereby
on nonneuronal peripheral organs, may importantly contribute
to reduce the negative effect of the overactivation of the ECS
described in association with obesity and related disorders.(C) Hepatic triglycerides (TG) content in WT mice fed with SD (white bar, n = 7), WT on HFD (black bar,
CB1-KO on HFD (gray bar, n = 8). *p < 0.05.
(D) Hormonal profile in WT mice fed with SD (white bar), WT on HFD (black bar), CaMK-CB1-KO on
insulin, and FFA: n = 20 per genotype and diet. Triglycerides and total cholesterol: n = 12. Glucose:
Data in (B)–(D) represent mean ± SEM. The values of the CaMK-CB1-WT and CB1-WT in SD or HFD w
Cell Metabolism 1EXPERIMENTAL PROCEDURES
Animals
Male CB1-KO mice, CaMK-CB1-KO mice (CB1 receptor
deletion in neurons expressing the Ca2+/calmodulin-
dependent kinase IIa), and their WT littermates were gen-
otyped as described (Marsicano et al., 2002; Monory
et al., 2006). Mutant animals were in a mixed genetic
background, with a predominant C57BL/6N contribution(seven backcrosses). Mice were housed in individual cages under conditions
of controlled temperature (24C) and illumination (12 hr light/12 hr dark cycle)
in the DIMORFIPA animal facilities, University of Bologna, Italy. All of the
procedures were approved by the Central Veterinary Office of Bologna
University in accordance with the European Community (86/609/EEC) guide-
lines for the care and use of laboratory animals. Animals were fed either with
a mouse SD containing 12.3 KJ/g (11% fat, 19% protein, 70% carbohydrate;
Dr. Piccioni Lab, Gessate, Milano, Italy), with an HFD having 18.9 KJ/g (40%
fat, 15% protein, 45% carbohydrate; Dottor Piccioni Lab), or with a super
HFD (SHFD) having 21.3 KJ/g (60.3% fat, 18.4% protein, 21.3% carbohy-
drate; TD.06414 Harlan Teklad, Italy). Eight-week-old mice were placed on
HFD or SHFD or were maintained on SD. Body weight was measured
twice a week starting at 8 weeks until 20 weeks of age (when not mentioned
otherwise).n = 6), CaMK-CB1-KO on HFD (red dashed bar, n = 8), and
HFD (red dashed bar), CB1-KO on HFD (gray bar). Leptin,
n = 12. ***p < 0.0005; **p < 0.005; *p < 0.05.
ere cumulated in (B) and (C) since not statistically different.
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CB1 Receptors and Energy MetabolismIn Situ Hybridization
All tissues were derived from mice on SD. In situ hybridization (ISH) and
DISH were performed using a radioactive or a nonradioactive (dig-labeled)
CB1-specific riboprobe and a nonradioactive (dig-labeled) GLP-1 in the hypo-
thalamus, NTS, and nodose ganglia or a dopamine b-hydroxylase (DBH)-
specific riboprobe in superior cervical sympathetic ganglia (Marsicano and
Lutz, 1999) (see Supplemental Information).
IHC and Immunofluorescence
Polyclonal goat antibody (ab) (1:900) against the C-terminal 31 amino acids
(443–473) of mouse CB1 was used to stain hypothalamus and brainstem
(Fukudome et al., 2004), and a polyclonal rabbit antiserum (1:300) against
the last 73 amino acid residues of rat CB1 (Wager-Miller et al., 2002) was
used to stain nodose ganglion (generous gift of Dr. K. Mackie, Indiana Univer-
sity, Bloomington, IN). The specificity of the CB1 antibodies was described
elsewhere (Makara et al., 2007; Wager-Miller et al., 2002). Anti-tyrosine
hydroxylase rabbit polyclonal ab (1:2000; Chemicon-Millipore, Temecula, CA
92590) detecting adrenergic nerve fibers was used in BAT. Biotinylated
donkey anti-goat IgG (1:500; Jackson Lab, West Grove, PA) for hypothalamus
and brainstem and rhodamine (TRITC)-conjugated affine pure donkey anti-
rabbit IgG (1:200 Jackson ImmunoResearch) for BAT were used as secondary
abs. For double-labeling immunofluorescence of nodose ganglia, a goat
polyclonal anti-HuC/D (a panneuronal marker) (Santa Cruz Biotechnology,
Inc. CA 95060) was used. As secondary abs, donkey anti-mouse IgG conju-
gated to fluorescein isothiocyanate (FITC) and rhodamine (TRITC)-conjugated
(Jackson ImmunoResearch) (both at 1:500) were used (see Supplemental
Information).
RNA Isolation and Real-Time PCR Analysis
RNA was isolated from tissues on SD or HFD (when indicated) mice and was
analyzed as described (Tedesco et al., 2008) (see Supplemental Information).
Primer sequences are in Table S1.
Immunoblot Analysis
The following antibodies were used: anti-PGC-1a (1: 1000, Cell Signaling),
anti-COX IV (1:500, Molecular Probes), anti-Cyt c (1:500, BD Bioscience),
anti-UCP-1 (1:1000, Calbiochem), and anti-GAPDH (1:20000 Histo-Line Labo-
ratories) (see Supplemental Information).
Food Intake and Feed Efficiency
Food intake of mice allowed to food and water ad libitum was measured twice
a week starting at 8 weeks until 20 weeks of age. Feed efficiency was calcu-
lated over the 12 weeks of diet as body weight gained per unit of energy intake
(g/KJ). For the other studies on food intake, see Supplemental Information.Figure 6. Increased Thermogenesis and Sympathetic Tone in CaMK-C
(A) Mitochondrial biogenesis and UCP1 mRNA levels in BAT of CaMK-CB1-WT (b
NRF-1, Tfam, COX IV, Cyt c mRNA level, and mitochondrial DNA amounts were a
versus CaMK-CB1-WT mice.
(B) Body temperature in CaMK-CB1-WT (black triangles) (n = 5) and CaMK-CB1
*p < 0.05; **p < 0.005.
(C) Metabolic rate in CaMK-CB1-WT (black triangles) (n = 5) and CaMK-CB1-KO
(D) Representative PET image showing 18F-FDG accumulation in the soprascapu
Axial section. (Bottom) Sagittal section.
(E) Quantification of 18F-FDG uptake (SUV) in the soprascapular BAT of CaMK-C
cold exposure and different treatments. The cohorts were composed of mice trea
vehicle + surgically denervation (n = 6 WT, n = 6 KO). For each cohort, the analysi
CaMK-CB1-WT vehicle; xp < 0.05 versus CaMK-CB1-KO vehicle; #p < 0.05 vers
(F) Plasma norepinephrine levels in WT (black bar, n = 12), CaMK-CB1-KO (dashe
WT. The values of the CaMK-CB1-WT and CB1-WT mice were grouped since no
(G) Representative PET image showing the uptake of 11C-meta-hydroxyephedrine
in basal state and after cold exposure.
(H) Representative PET image showing 11C-meta-hydroxyephedrine uptake (at 24
(10 mg/kg) for 32 days.
Radioactive counts in (D), (G), and (H) are expressed as standard uptake values (S
(F) represent mean ± SEM. See also Figure S2.
CHormone and Metabolite Assays
Plasma leptin was measured by Mouse Leptin RIA kit ML-82k (Millipore Corpo-
ration), insulin by Rat Insulin RIA kit RI-13K (Millipore Corporation), FFA by
a colorimetric method (Wako Chemicals, Richmond, VA), triglycerides and
total cholesterol by spectrophotometric enzymatic test (Roche Diagnostics,
Mannheim, Germany), and glucose by the Breeze glucometer (Bayer). Plasma
catecholamines were determined by high-performance liquid chromatography
(Grossi et al., 1991). Blood for cathecolamines determination was obtained
from nonanesthetized animals via surgically implanted intracardiac catheters.
Haepatic lipids were extracted in chloroform/methanol 2:1 (0.01% BHT) and
analyzed by BV-K622-100 kit (BoVision, Mountain View, CA).
In Vivo Quantification of Adipose Tissue
Mice were placed under anesthesia with 5% sevoflurane and oxygen supple-
mentation (1 l/min) and scanned in an in vivo microcomputed tomography
(micro-CT) scanner (eXplore Locus, GE, Milwaukee) at an isometric resolution
of 90 mm (see Supplemental Information).
Energy Expenditure
Animals were kept individually in type II Makrolon cages inside a climate
chamber. RQ and metabolic rate data were collected every hour in animals
with free access to food and water. Some experiments were performed in
two consecutive days. On day 1, mice were studied in their physiological
conditions at ambient temperature. At the beginning of the light phase of
day 2, mice were treated with rimonabant (10 mg/kg i.p.). Experiments under
cold conditions were performed with an initial period of acclimation of the mice
in the chambers (at 24C for 3 hr), followed by a lowering of chambers temper-
ature to 6C (see Supplemental Information).
Telemetric Recording of Body Temperature
Animals were i.p. implanted with calibrated temperature transmitters (Mini-
Mitter, Model X, Sunriver, Oregon, accuracy 0.1C) under ketamine-hydro-
chloride anesthesia (50 mg*kg1) and 1%–2% isoflurane. The detection of
the transmitter signals was accomplished by a radio receiver and processed
by a microcomputer system.
Food and Feces Energy Content
Energy content of food and energy loss via the feces were determined using
bomb calorimetry (IKA-Calorimeter C 5000, IKA-Werke GmbH & Co. KG, Stau-
fen, Germany).
Mitochondrial DNA Analysis and Citrate Synthase Activity
Mitochondrial DNA analysis was performed and citrate synthase activity was
measured as described in Tedesco et al., 2008.B1-KO on High-Fat Diet
lack bars) and CaMK-CB1-KO mice (dashed red bars) fed with HFD. PGC-1a,
nalyzed by QT-PCR. CaMK-CB1-WT: n = 7; CaMK-CB1-KO: n = 8. **p < 0.005
-KO mice (red triangles) (n = 6) on HFD during 6 hr of cold exposure (+6C).
mice (red triangles) (n = 6) on HFD during 6 hr at +6C. ***p < 0.0005.
lar BAT (arrows) of a CaMK-CB1-WT and CaMK-CB1-KO mouse at +6
C. (Top)
B1-WT (black bar) and CaMK-CB1-KO mice (dashed red bar) under HFD after
ted with: vehicle (n = 12 WT, n = 9 KO), vehicle + 6-0H-DA (n = 6 WT, n = 6 KO),
s was repeated on the same mice after rimonabant treatment. *p < 0.05 versus
us CaMK-CB1-WT rimonabant.
d red bars, n = 7), and CB1-KO mice (gray bar, n = 9) on HFD. *p < 0.05 versus
t statistically different.
in the BAT (arrow) of WT (n = 4), CaMK-CB1-KO (n = 4), andCB1-KO (n = 3) mice
C) in the BAT (arrow) of WT mice chronically treated with vehicle or rimonabant
UV); smaller insets in (G) and (H) represent sagittal view. Data in (A–C), (E), and
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CB1 Receptors and Energy MetabolismSmall Animal PET Studies
For 18F-FDG studies, 20-week-old mice were imaged in two different sessions.
In the first, 8 hr fasted mice were placed at 24C and i.p. treated with a vehicle
solution; 1 hr later, mice were moved to a cold chamber (6C) for 3 hr. Mice
were then lightly anesthetized (gas sevofluorane), injected with 18F-FDG
(15 MBq), allowed to awake, and placed in a cold chamber for 1 hr (phase of
tracer uptake). Scans were performed with a PET system (Explore Vista, GE)
in animals treated with vehicle (3% DMSO, 1% Tween80 in saline solution)
or vehicle + sympathetic denervation and repeated after 5 days of stabilization
in the same animals treated with rimonabant (10 mg/kg i.p.). Control mice after
sympathectomy (vehicle of 6-hydroxydopamine hydrobromide [6-OH-DA] and
sham-operated mice) did not present different values of FDG uptake
compared to WT mice treated with the vehicle of rimonabant (data not shown);
thus, they were not included in the analysis.
For 11C-meta-hydroxyephedrine studies, PET scan started immediately
after the tracer injection (20 MBq) in the tail vein of anaesthetized animals.
Imaging was first performed on 20-week-old animals at 24C and then
repeated (after 5 days) in the same animals exposed to cold (6C) for 3 hr.
Data for accumulation of 18F-FDG and 11C-meta-hydroxyephedrine on small
animal PET images were expressed as standard uptake values (SUV) repre-
senting radioactive counts per gram of tissue, divided by injected dose of
radioactivity per gram of animal weight. To correctly identify BAT uptake of
the tracers, a CT reference image was coregistered with the PET image for
each scan as described in Galie` et al., 2007.Sympathectomy
For the chemical sympathectomy, mice were i.p. treated with injections of
80 mg/kg of 6-OH-DA in 0.1% ascorbic acid or vehicle daily for 3 consecutive
days. Surgical sympathectomy of BAT was performed by cutting each of the
nerve bundles projecting into the left and the right soprascapular pads. For
the sham-operated animals, the BAT and the nerves were exposed, but not
transected. Animals were allowed to recover for 10 days before testing. For
histological verification of denervation, see Figure S2C.Statistics
Results are expressed as mean ± SEM. Statistical analysis was performed by
unpaired two-tailed Student’s t test or by analysis of variance (ANOVA) with
appropriate posthoc tests. The software GraphPad Prism 5.0 was used. A p
value less than 0.05 was considered statistically significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at
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